The Recruitment of AMP-activated Protein Kinase to Glycogen Is Regulated by Autophosphorylation

Yvonne Oligschlaeger, Marie Miglianico, Dipanjan Chanda, Roland W. Scholz, Ramon F. Thali, Roland Tuerk, David Stapleton, Paul R. Gooley, Dietbert Neumann

Journal of Biological Chemistry · 2015 · 40 citations · 52 references

DOIFull text

Open access

Concepts

Abstract

The mammalian AMP-activated protein kinase (AMPK) is an obligatory αβγ heterotrimeric complex carrying a carbohydrate-binding module (CBM) in the β-subunit (AMPKβ) capable of attaching AMPK to glycogen. Nonetheless, AMPK localizes at many different cellular compartments, implying the existence of mechanisms that prevent AMPK from glycogen binding. Cell-free carbohydrate binding assays revealed that AMPK autophosphorylation abolished its carbohydrate-binding capacity. X-ray structural data of the CBM displays the central positioning of threonine 148 within the binding pocket. Substitution of Thr-148 for a phospho-mimicking aspartate (T148D) prevents AMPK from binding to carbohydrate. Overexpression of isolated CBM or β1-containing AMPK in cellular models revealed that wild type (WT) localizes to glycogen particles, whereas T148D shows a diffuse pattern. Pharmacological AMPK activation and glycogen degradation by glucose deprivation but not forskolin enhanced cellular Thr-148 phosphorylation. Cellular glycogen content was higher if pharmacological AMPK activation was combined with overexpression of T148D mutant relative to WT AMPK. In summary, these data show that glycogen-binding capacity of AMPKβ is regulated by Thr-148 autophosphorylation with likely implications in the regulation of glycogen turnover. The findings further raise the possibility of regulated carbohydrate-binding function in a wider variety of CBM-containing proteins.Background: AMP-activated protein kinase (AMPK) is a current drug target. AMPK can attach to glycogen granules.Results: Autophosphorylation of AMPK prevents its association with glycogen.Conclusion: Subcellular localization of AMPK is affected by the kinase autophosphorylation status.Significance: Understanding the regulation of AMPK at subcellular level is crucial for the currently pursued drug targeting approach. The mammalian AMP-activated protein kinase (AMPK) is an obligatory αβγ heterotrimeric complex carrying a carbohydrate-binding module (CBM) in the β-subunit (AMPKβ) capable of attaching AMPK to glycogen. Nonetheless, AMPK localizes at many different cellular compartments, implying the existence of mechanisms that prevent AMPK from glycogen binding. Cell-free carbohydrate binding assays revealed that AMPK autophosphorylation abolished its carbohydrate-binding capacity. X-ray structural data of the CBM displays the central positioning of threonine 148 within the binding pocket. Substitution of Thr-148 for a phospho-mimicking aspartate (T148D) prevents AMPK from binding to carbohydrate. Overexpression of isolated CBM or β1-containing AMPK in cellular models revealed that wild type (WT) localizes to glycogen particles, whereas T148D shows a diffuse pattern. Pharmacological AMPK activation and glycogen degradation by glucose deprivation but not forskolin enhanced cellular Thr-148 phosphorylation. Cellular glycogen content was higher if pharmacological AMPK activation was combined with overexpression of T148D mutant relative to WT AMPK. In summary, these data show that glycogen-binding capacity of AMPKβ is regulated by Thr-148 autophosphorylation with likely implications in the regulation of glycogen turnover. The findings further raise the possibility of regulated carbohydrate-binding function in a wider variety of CBM-containing proteins. Background: AMP-activated protein kinase (AMPK) is a current drug target. AMPK can attach to glycogen granules. Results: Autophosphorylation of AMPK prevents its association with glycogen. Conclusion: Subcellular localization of AMPK is affected by the kinase autophosphorylation status. Significance: Understanding the regulation of AMPK at subcellular level is crucial for the currently pursued drug targeting approach.

References

52